Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY
Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY
Biodexa製藥2024年上半年每股收益爲(0.1便士)，同比下降至(3.6便士)
For the year six month period ended June 30
截至6月30日的六個月期間
| Note |
2024 unaudited £'000 |
2023 unaudited £'000 |
|
| Revenue | - | 298 | |
| Research and development costs | (2,189) | (2,251) | |
| Administrative costs | (2,034) | (2,291) | |
| Loss from operations | (4,223) | (4,244) | |
| Finance income | 3 | 839 | 410 |
| Finance expense | 3 | (49) | (22) |
| Loss before tax | (3,433) | (3,856) | |
| Taxation | 4 | 125 | 288 |
| Loss for the period attributable to the owners of the parent | (3,308) | (3,568) | |
| Total comprehensive loss attributable to the owners of the parent | (3,308) | (3,568) | |
| Loss per share | |||
| Basic and diluted loss per ordinary share – pence | 5 | (0.1p) | (3.6)p |
| 單張債券 | 2024 未經審計 £'000 |
2023 未經審計 £'000 |
|
| 營業收入 | - | 298 | |
| 研究開發費用 | (2,189) | （2,251） | |
| 行政成本 | (2,034) | (2,291) | |
| 經營虧損 | (4,223) | (4,244) | |
| 財務收益 | 3 | 839 | 410 |
| 財務費用 | 3 | (49) | (22) |
| 稅前虧損 | （3,433） | (3,856) | |
| 稅收 | 4 | 125 | 288 |
| 歸屬於母公司所有者的期間虧損 | (3,308) | (3,568) | |
| 歸屬於母公司所有者的綜合虧損總額 | (3,308) | (3,568) | |
| 每股虧損 | |||
| 每股普通股基本和稀釋虧損-便士 | 5 | （0.1便士） | (3.6)p |